NeoStem falls on Phase II miss

NeoStem Inc. (NASDAQ:NBS) plunged $2 (30%) to $4.78 on Tuesday after reporting that its NBS-10 stem cell therapy

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE